3 Stocks Raising The Drugs Industry Higher

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 78 points (0.5%) at 16,438 as of Thursday, March 6, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,775 issues advancing vs. 1,148 declining with 152 unchanged.

The Drugs industry currently is unchanged today versus the S&P 500, which is up 0.4%. Top gainers within the industry include Teva Pharmaceutical Industries ( TEVA), up 1.6%, AbbVie ( ABBV), up 1.2%, Novartis ( NVS), up 1.2%, Merck ( MRK), up 1.0% and Amgen ( AMGN), up 0.5%. On the negative front, top decliners within the industry include Valeant Pharmaceuticals International ( VRX), down 2.3%, Mylan ( MYL), down 1.5% and Actavis ( ACT), down 1.5%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. Sanofi ( SNY) is one of the companies pushing the Drugs industry higher today. As of noon trading, Sanofi is up $0.52 (1.0%) to $52.32 on light volume. Thus far, 277,815 shares of Sanofi exchanged hands as compared to its average daily volume of 1.7 million shares. The stock has ranged in price between $52.18-$52.48 after having opened the day at $52.40 as compared to the previous trading day's close of $51.80.

Sanofi researches, develops, manufactures, and markets healthcare products. The company operates in Pharmaceuticals, Human Vaccines, and Animal Health segments. Sanofi has a market cap of $138.5 billion and is part of the health care sector. Shares are down 3.1% year-to-date as of the close of trading on Wednesday. Currently there are 2 analysts who rate Sanofi a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Sanofi as a buy. The company's strengths can be seen in multiple areas, such as its increase in net income, revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins and growth in earnings per share. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Sanofi Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Biogen Idec ( BIIB) is up $8.28 (2.4%) to $347.28 on average volume. Thus far, 761,515 shares of Biogen Idec exchanged hands as compared to its average daily volume of 1.4 million shares. The stock has ranged in price between $345.00-$353.00 after having opened the day at $346.86 as compared to the previous trading day's close of $339.00.

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Biogen Idec has a market cap of $81.1 billion and is part of the health care sector. Shares are up 22.7% year-to-date as of the close of trading on Wednesday. Currently there are 14 analysts who rate Biogen Idec a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Biogen Idec as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and solid stock price performance. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Biogen Idec Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Johnson & Johnson ( JNJ) is up $0.77 (0.8%) to $93.36 on light volume. Thus far, 2.0 million shares of Johnson & Johnson exchanged hands as compared to its average daily volume of 8.4 million shares. The stock has ranged in price between $93.02-$93.65 after having opened the day at $93.17 as compared to the previous trading day's close of $92.59.

Johnson & Johnson, together with its subsidiaries, is engaged in the research and development, manufacture, and sale of various products in the health care field worldwide. The company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Johnson & Johnson has a market cap of $264.0 billion and is part of the health care sector. Shares are up 1.9% year-to-date as of the close of trading on Wednesday. Currently there are 9 analysts who rate Johnson & Johnson a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Johnson & Johnson as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, increase in stock price during the past year, impressive record of earnings per share growth and compelling growth in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Johnson & Johnson Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Dow Wavers, S&P 500 Lower as Amazon Rises, Apple and P&G Slump

Dow Wavers, S&P 500 Lower as Amazon Rises, Apple and P&G Slump

Soaring Nickel Prices Could Be Bad News for Electric Carmakers Like Tesla

Soaring Nickel Prices Could Be Bad News for Electric Carmakers Like Tesla

Video: The Road to S&P 500 2,800 Is 'Slow and Choppy'

Video: The Road to S&P 500 2,800 Is 'Slow and Choppy'

Let the Najarian Brothers Help You Generate Income With Options

Let the Najarian Brothers Help You Generate Income With Options

Oil Stocks Jump as Global Crude Oil Rally Gains Steam

Oil Stocks Jump as Global Crude Oil Rally Gains Steam